Know Cancer

or
forgot password

Prevalence of Hypogonadism in Male Cancer Patients


N/A
18 Years
N/A
Not Enrolling
Male
Cancer, Hypogonadism

Thank you

Trial Information

Prevalence of Hypogonadism in Male Cancer Patients


Inclusion Criteria:



1. Male subjects ≥ 18 years of age with histological diagnosis of cancer for cancer
group.

2. Provide written informed consent prior to screening.

3. Histological diagnosis of cancer other than non-melanoma skin cancer for the two
cancer groups.

Exclusion Criteria:

1. Concomitant use of GH, Megestrol, Marinol, or any other anabolic agent, appetite
stimulant (including corticosteroids other than dexamethasone at the time of IV
chemotherapy administrations), tube feedings, or parenteral nutrition during the 3
months prior to entering the study.

2. Participation in a clinical trial with investigational agents within 1 month of
enrollment.

3. Prior or current use of other medications that interfere with gonadal axis
(androgens, estrogens, anti-androgens, etc).

Type of Study:

Observational

Study Design:

Time Perspective: Cross-Sectional

Principal Investigator

Jose M Garcia, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Baylor College of Medicine, Michael E. DeBakey VAMC

Authority:

United States: Institutional Review Board

Study ID:

H-19709

NCT ID:

NCT00472940

Start Date:

November 2006

Completion Date:

Related Keywords:

  • Cancer
  • Hypogonadism
  • Cancer
  • Hypogonadism
  • testosterone
  • cachexia
  • Hypogonadism

Name

Location

Michael E. DeBakey Veterans Affairs Medical CenterHouston, Texas  77030